Full Text View
Tabular View
No Study Results Posted
Related Studies
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma (ORIENTAL)
This study is currently recruiting participants.
Verified March 2013 by Taiho Pharmaceutical Co., Ltd.
Study NCT01465464   Information provided by Taiho Pharmaceutical Co., Ltd.

First Received on November 1, 2011.   Last Updated on March 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatocellular Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Hepatocellular
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Orantinib (TSU-68)
Placebo
Sponsors listed in this trial
Taiho Pharmaceutical Co., Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services